KRAS K117N

CI-VAR-00002071Explore in graph →NP_004976.2:p.Lys117AsnNM_004985.4:c.351A>TClinVar 375964 CIViC 1120 rs770248150

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Clear Cell Sarcoma of Soft Tissue1
KRAS K117N	Vemurafenib	Predictive	D	Supports Resistance	—	submitted	EID4425 In an in vitro study, A375 cell lines expressing BRAF V600E (a known sensitizing mutation to vemurafenib) and KRAS K117N co-mutations demonstrated reduced sensitivity to vemurafenib treatment, compare… (full text at CIViC) PMID 22205714 · Su et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375964	Likely pathogenic	criteria provided, single submitter	1	Mosaic KRAS-related syndrome; Neoplasm; Neuroblastoma	somatic	3	Jan 28, 2026	clinvar